Blue Water Acquisition Corp.

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarus Therapeutics Holdings

Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021

Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies

GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (Nasdaq: BLUW), a special purpose acquisition company (“Blue Water”), today announced that its stockholders have voted to approve the proposed business combination (the “Business Combination”) with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (“Clarus”) at its special meeting of stockholders (the “Special Meeting”) held today, August 27, 2021.

Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

Blue Water Acquisition (BLUW) stock is heading higher on Thursday ahead of the SPAC's upcoming shareholder meeting and recent rumors. The post BLUW Stock: 11 Things to Know About Blue Water SPAC Amid Short-Squeeze Rumors appeared first on InvestorPlace.

BLUW Stock: 11 Things to Know About Blue Water SPAC Amid Short-Squeeze Rumors

Good Works Acquisition Corp.

Tortoise Acquisition Corp - Ordinary Shares - Class A

Most SPACs have redemption rights, which give shareholders the right to sell their shares back to the acquisition company for $10 per share.

A handful of heavily shorted SPACs are being squeezed higher as investors redeem shares ahead of final merger

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) (“Blue Water” or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planned business combination with Clarus Therapeutics, Inc. ("Clarus"), announced today that the special meeting of its stockholders (the “Special Meeting”) originally scheduled for Thursday, August 12, 2021, is being postponed to Friday, August 27, 2021.

Blue Water Acquisition Corp. Announces Change of Special Meeting of Shareholders Date to August 27, 2021

GREENWICH, Conn., July 30, 2021 /PRNewswire/ --  Blue Water Acquisition Corp. (Nasdaq: BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced merger agreement pursuant to which Clarus Therapeutics, Inc. ("Clarus") will merge with a wholly-owned subsidiary of Blue Water (the "Business Combination") and seek to become a publicly listed company.

Blue Water Acquisition Corp. Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Therapeutics, Inc.

NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics ("HavaH"), an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormone/immune interface, today announced a licensing agreement whereby Clarus will acquire the exclusive worldwide (excluding Australia) development and commercialization rights for HAVAH T+Ai™ (CLAR-121).

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

NEW YORK, May 4, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Blue Water Acquisition Corp. ("BLUW" or the "Company") ( BLUW) relating to its proposed merger with Clarus Therapeutics, Inc. Under the terms of the agreement, BLUW will acquire Clarus through a reverse merger, with Clarus emerging as a publicly traded company. The investigation focuses on whether Blue Water Acquisition Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Blue Water Acquisition Corp. - BLUW

News for Blue Water Acquisition Corp. Stock (BLUW)